Skip to main content
. 2023 May 4;16:1487–1498. doi: 10.2147/JPR.S388896

Table 1.

List of Publications Found in PubMed That are Associated with Human Clinical Trial Targeting the Pain Gene SCN9A and Its Protein Expression Nav1.7 as of December 2022

Publication Date Study Title Conditions Interventions Phase Lead Sponsor
March 2020 Differential effect of lacosamide on Nav1.7 variants from responsive and non-responsive patients with small fiber neuropathy Small fiber neuropathy Lacosamide I Yale University School of Medicine, New Haven, CT
March 2020 Lack of detection of the analgesic properties of PF-05089771, a selective Na v 1.7 inhibitor, using a battery of pain models in healthy subjects Battery of human evoked pain models PF-05089771 alone and PF-05089771 concomitantly with pregabalin as treatment arms with pregabalin, ibuprofen, and placebo as control arms I Centre for Human Drug Research, Leiden, The Netherlands
January 2020 Evaluation of the pharmacokinetic interaction between the voltage- and use-dependent Nav1.7 channel blocker vixotrigine and carbamazepine in healthy volunteers Peripheral neuropathic pain conditions, including trigeminal neuralgia Vixotrigine Carbamazepine I Biogen, Cambridge, Massachusetts, USA
September 2019 Safety, tolerability, and pharmacokinetics of GDC-0276, a novel Na V 1.7 inhibitor, in a first-in-human, single- and multiple-dose study in healthy volunteers Pain relief GDC-0276 as powder-in-capsule (PIC) or cyclodextrin solution (CD) single doses I Genentech, Inc.
February 2019 Lacosamide in patients with Nav1.7 mutations-related small fiber neuropathy: a randomized controlled trial Nav1.7 mutations-related small fiber neuropathy Lacosamide I Department of Neurology, School of Mental Health and Neuroscience, Maastricht University Medical Center, Maastricht, The Netherlands
January 2019 Effects of a state- and use-dependent Nav1.7 channel blocker on ambulatory blood pressure: a randomized, controlled crossover study Neuropathic pain conditions Vixotrigine I Immunovant, Inc., Durham, NC, USA.
December 2018 Challenges recruiting to a proof-of-concept pharmaceutical trial for a rare disease: the trigeminal neuralgia experience Trigeminal neuralgia Vixotrigine IIa Facial Pain Unit, Division of Diagnostic, Surgical and Medical Sciences, Eastman Dental Hospital, University College London Hospitals NHS Foundation Trust/University College London, London, UK
August 2018 Efficacy of the Nav1.7 blocker PF-05089771 in a randomized, placebo-controlled, double-blind clinical study in subjects with painful diabetic peripheral neuropathy. Diabetic peripheral neuropathy PF-05089771 I Pfizer WRD, Pain and Neuroscience Research Unit, Cambridge, UK
April 2017 Safety and efficacy of a topical sodium channel inhibitor (TV-45070) in patients with postherpetic neuralgia (PHN): a randomized, controlled, proof-of-concept, crossover study, with a subgroup analysis of the Nav1.7 R1150W genotype Postherpetic meuralgia Topical sodium channel inhibitor (TV-45070) I Xenon Pharmaceuticals Inc.
Apriil 2017 Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial Trigeminal neuralgia BIIB074 IIa Facial Pain Unit, Division of Diagnostic, Surgical and Medical Sciences, Eastman Dental Hospital, University College London Hospitals NHS Foundation Trust/University College London, London, UK
July 2016 Clinical micro-dose studies to explore the human pharmacokinetics of four selective inhibitors of human Nav1.7 voltage-dependent sodium channels Chronic pain through inhibition of Nav1.7 channels Intravenous and oral PK of four compounds (PF-05089771, PF-05150122, PF-05186462 and PF-05241328) I Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide R&D, Sandwich, Kent, UK
June 2016 Efficacy, safety, and tolerability of lacosamide in patients with gain-of-function Nav1.7 mutation-related small fiber neuropathy: study protocol of a randomized controlled trial-The LENSS study Gain-of-function Nav1.7 mutation-related small fiber neuropathy Lacosamide I Department of Neurology, School of Mental Health and Neuroscience, Maastricht University Medical Center
April 2016 Pharmacological reversal of a pain phenotype in iPSC-derived sensory neurons and patients with inherited erythromelalgia Inherited erythromelalgia PF-05089771 1 Pfizer Neuroscience and Pain Research Unit, The Portway Building, Granta Park, Cambridge CB21 6GS, UK.
October 2011 Treatment of Na(v)1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker Inherited erythromelalgia XEN402 1 Xenon Pharmaceuticals Inc., Burnaby, British Columbia, Canada